8 results
The main objective of this study is to investigate whether HRM is able to predict bolus transport of solids and liquids in the oesophagus as adequately as the gold standard, i.e. videofluoroscopy.
Primary objectives: 1. Safety 2. Practical feasibility Secondary objectives: 1. angiographic patency rate before PCI 2. Cumulative ST-segment resolution. 3. myocardial infarct characteristics 4. Myocardial perfusion on contrast echocardiography 5.…
Primary objectives:Dose Escalation• To assess the safety and tolerability of JDQ443 single agent and JDQ443 in combination with TNO155, JDQ443 in combination with tislelizumab, and JDQ443 in combination with TNO155 and tislelizumab, and to identify…
Primary:• Compare progression-free survival (PFS) as assessed by the Independent Review Committee (IRC) per Response Evaluation Criteriain Solid Tumors (RECIST) Version (v) 1.1 in ociperlimab plus tislelizumab (Arm A) versus Durvalumab (Arm C) among…
Safety Run-in (SRI) part:To confirm the recommended phase 2 dose (RP2D) of NIS793 or any other investigational drug(s), in combination with SOC anti-cancer therapy. In protocol amendment 1, an arm with tislelizumab has been added. In this arm, the…
To compare the relative efficacy of sonothrombolysis in the acute management of STEMI following primary percutaneous coronary intervention [PCI] in patients with persistent ST elevation compared with standard of care.
Primary objective:- To compare the efficacy of zanidatamab in combination with chemotherapy or in combination with chemotherapy and tislelizumab to the efficacy of trastuzumab in combination with chemotherapy in subjects with unresectable locally…
Primary:• To compare progression free survival (PFS) between Arm A (ociperlimab in combination with tislelizumab) and Arm B (pembrolizumab followed by placebo) in the Intent to Treat (ITT) Analysis Set as assessed by investigators according to…